CYT006-AngQb

Identification

Name
CYT006-AngQb
Accession Number
DB05739
Description

CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Investigated for use/treatment in hypertension.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

The so called renin-angiotensin system (RAS) is an important regulator of blood pressure and has already been successfully targeted by three major classes of antihypertensive drugs: by ACE inhibitors, by ARBs and by renin inhibitors. However, like other antihypertensives, they all have to be self-administered daily and don't provide a good solution for improving patient compliance. CYT006-AngQb is a therapeutic vaccine designed to instruct the patient’s immune system to produce a specific anti-angiotensin II antibody response. Angiotensin II is a small hormone in the body and part of the RAS. It causes blood vessels to narrow, resulting in an increase in blood pressure. Vaccination of humans with CYT006-AngQb has been shown to induce angiotensin II specific antibodies that should inhibit binding of angiotensin II to its receptors and thus reduce the narrowing of blood vessels. As first clinical data indicate, the achieved blood pressure reduction was particularly pronounced in the early morning when the vaccine effect suppressed the naturally occurring morning rise in blood pressure.

TargetActionsOrganism
UType-1 angiotensin II receptorNot AvailableHumans
UType-2 angiotensin II receptorNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life

4 months

Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910202
Wikipedia
CYT006-AngQb

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2CompletedTreatmentMild Essential Hypertension / Moderate Essential Hypertension1
1, 2CompletedTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor antagonist activity
Specific Function
Receptor for angiotensin II. Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation.
Gene Name
AGTR2
Uniprot ID
P50052
Uniprot Name
Type-2 angiotensin II receptor
Molecular Weight
41183.45 Da

Drug created on November 18, 2007 18:27 / Updated on June 12, 2020 16:52